Research topics:

Investigation of personalized therapies for neuroendocrine tumors of the gastroenteropancreatic and bronchial system, pheochromocytomas and paragangliomas in vitro, in vivo and in human tumor primary cultures, novel molecular-targeted and genetically-driven therapies, therapy resistance, radionuclide therapy, prognostic markers (precision oncology)

Projects:

• Else Kröner-Fresenius Foundation (PI Svenja Nölting): Characterisation and overcoming mechanisms of resistance to the mTORC1 inhibitor everolimus in vitro in two human pancreatic neuroendocrine tumor cell lines (BON RR1, BON RR2) with stable resistance to everolimus, in vivo in an orthotopic intrapancreatic xenograft mouse model and in human tumor tissue by utilizing signalling pathway analysis (2019-2021)
• Novartis: Young Investigators in Neuroendocrine Neoplasia Germany Program (YING) (PI Svenja Nölting): Therapy resistance in neuroendocrine neoplasia (2019-2021)
• Deutsche Forschungsgemeinschaft (DFG), SFB CRC-TRR-205, 2nd funding period (Co-PI Svenja Nölting): The molecular pathology of PPGLs and genetically-driven molecular-targeted therapies: Towards precision medicine
• Exzellenz-Netzwerk für neuroendokrine Tumoren München (NeoExNETM) registry, (PI C. J. Auernhammer)
• Radiosensitizing and somatostatin receptor re-expression in neuroendocrine tumor cells: Translational concepts for peptide receptor chemo radionuclide therapy (PRCRT) (PI C. J. Auernhammer & Svenja Nölting)

• PI: Prof. Dr. Christoph J. Auernhammer
• PI: Prof. Dr. Svenja Nölting
• Postdoc Sonal Prasad (collaboration with Charité Berlin)
• PHD Ajay Mohan (collaboration with Charité Berlin)
• TA: Julian Maurer
• TA: Gerald Spöttl
• Study nurse: Nina Schmidt